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and red blood cell invasion
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Ute Woehlbier1,3, Christian Epp*1,4, Fiona Hackett2, Michael J Blackman2 and Hermann Bujard1

Abstract
Background: Plasmodium falciparum merozoites expose at their surface a large protein complex, which is composed
of fragments of merozoite surface protein 1 (MSP-1; called MSP-183, MSP-130, MSP-138, and MSP-142) plus associated
processing products of MSP-6 and MSP-7. During erythrocyte invasion this complex, as well as an integral membrane
protein called apical membrane antigen-1 (AMA-1), is shed from the parasite surface following specific proteolysis.
Components of the MSP-1/6/7 complex and AMA-1 are presently under development as malaria vaccines.
Methods: The specificities and effects of antibodies directed against MSP-1, MSP-6, MSP-7 on the growth of blood
stage parasites were studied using ELISA and the pLDH-assay. To understand the mode of action of these antibodies,
their effects on processing of MSP-1 and AMA-1 on the surface of merozoites were investigated.
Results: Antibodies targeting epitopes located throughout the MSP-1/6/7 complex interfere with shedding of MSP-1,
and as a consequence prevent erythrocyte invasion. Antibodies targeting the MSP-1/6/7 complex have no effect on
the processing and shedding of AMA-1 and, similarly, antibodies blocking the shedding of AMA-1 do not affect
cleavage of MSP-1, suggesting completely independent functions of these proteins during invasion. Furthermore,
some epitopes, although eliciting highly inhibitory antibodies, are only poorly recognized by the immune system
when presented in the structural context of the intact antigen.
Conclusions: The findings reported provide further support for the development of vaccines based on MSP-1/6/7 and
AMA-1, which would possibly include a combination of these antigens.
Background
The severe pathophysiological manifestations of malaria
caused by Plasmodium falciparum are a direct consequence of the parasite's blood stage replication cycle, during which merozoites repeatedly invade, multiply within,
and destroy red blood cells (RBCs). A number of parasite
proteins are involved in RBC invasion, of which some,
such as MSP-1, MSP-6 and MSP-7, are constitutively
exposed at the merozoite surface, while others like apical
membrane antigen 1 (AMA-1) are translocated to the
merozoite surface only during invasion. All these proteins
undergo extensive proteolytic processing at around the
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point of invasion (Figure 1), and at least two of them MSP-1 and AMA-1 - are essential in asexual blood-stages
[1,2], making them and their maturation potential targets
for therapeutic interventions.
MSP-1, which constitutes the major protein component
at the merozoite surface [3], is synthesized as a ~190 kDa
precursor [4] which is deposited at the parasite plasma
membrane via a GPI anchor. During the final stages of
merozoite maturation, just prior to schizont rupture,
MSP-1 is cleaved by a parasite subtilisin-like protease
called PfSUB1 into four major subunits, MSP-183, MSP130, MSP-138, and MSP-142, which remain non-covalently
associated [5,6]. The MSP-1 complex interacts with processed forms of MSP-6 and MSP-7, (called MSP-636 and
MSP-722) which are thereby peripherally attached to the
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Figure 1 Primary structure and processing of P. falciparum 3D7 MSP-1, MSP-6, MSP-7 and AMA-1. SS, signal sequence; GA, GPI anchor; PS, prosequence; TM, transmembrane domain. (A) Outline of the MSP-1 precursor. The grey arrows indicate the sites of primary processing of the precursor
protein into its major subunits MSP-183, MSP-130, MSP-138, and MSP-142 as defined by Stafford et al., 1994 [42] and Koussis et al., 2009 [6]. A secondary
proteolytic cleavage mediated by PfSUB2 (black arrow) occurs during invasion, cleaving MSP-142 into MSP-133 and MSP-119. (B) AMA-1 is synthesized
as an 83 kDa precursor protein containing a C-terminal transmembrane domain (TM). After targeting to the micronemes the N-terminal pro-sequence
(PS) is removed, resulting in AMA-166, which appears at the merozoite surface at the time of schizont rupture. During invasion AMA-166 is proteolytically cleaved by PfSUB2 (black arrow) resulting in release of AMA-148/44 [14,15]. MSP-6 (C) and MSP-7 (D) are peripheral merozoite surface proteins,
membrane-bound through non-covalent associations with MSP-1. MSP-6 is processed into MSP-636. MSP-7 is initially cleaved into MSP-733 [9]. Around
the time of merozoite release from the newly ruptured schizont, MSP-733 is further cleaved into MSP-722 and MSP-719 [9,10].

parasite surface [7-11]. Invasion of RBCs requires a second processing event, which converts MSP-142 into MSP133 plus a 10 kDa GPI-anchored C-terminal species called
MSP-119, which contains tandem epidermal growth factor (EGF)-like domains (Figure 1A). As a result of this
processing, the entire MSP-1/6/7 complex is shed from
the parasite's surface, except for MSP-119 which is carried
into the newly invaded erythrocyte [12].
AMA-1 is initially trafficked as an 83 kDa protein to
apical merozoite secretory organelles called micronemes.
There, an N-terminal "prosequence" is removed resulting
in a 66 kDa processing product called AMA-166. Upon
schizont rupture AMA-166 is released from micronemes
to become distributed across the merozoite surface,
where, at around the point of invasion, it is proteolytically
cleaved just upstream of its transmembrane domain. This
results in the release of a fragment, comprising the bulk
of the AMA-1 ectodomain (called AMA-148/44) from the
parasite surface. As a result, only the residual membranebound AMA-1 juxtamembrane 'stub' region and associated cytoplasmic domain are transferred into the host
RBC [13-15].
Shedding of both MSP-1 and AMA-1 (referred to in
both cases as secondary processing) is catalyzed by a second, membrane-bound merozoite subtilisin-like 'shed-

dase' called PfSUB2, which is released from apical
organelles called micronemes onto the merozoite surface
at or just prior to invasion [14,16]. For both, MSP-1 and
AMA-1, antibodies have been identified which prevent
proteolytic processing and RBC invasion in vitro [17-20].
In the case of MSP-1, detailed characterization of a panel
of monoclonal antibodies targeting conformational
epitopes within the C-terminal EGF-like domains
revealed that only those that inhibited conversion of
MSP-142 into MSP-133 and MSP-119 also prevented invasion [18,21]. Whether antibodies targeting other epitopes
within MSP-1/6/7 can block secondary processing and
shedding of the complex was hitherto unknown. It is also
not known whether antibodies that block shedding of
parasite surface proteins by PfSUB2 only affect shedding
of their cognate target antigen, or whether they can act in
a non-antigen selective manner, thereby suggesting some
direct cooperation between these surface proteins during
the invasion process.
Recent studies showed that antibodies targeting
epitopes throughout MSP-1, MSP-6 and MSP-7 efficiently inhibit parasite growth in vitro [11,22]. To gain
insight into the mechanisms by which these potentially
protective antibodies may act, the effects of these and
other invasion-inhibitory antibodies on secondary pro-
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cessing of MSP-1 and AMA-1 have been examined. The
current study shows that antibodies targeting numerous
epitopes located throughout the multipartite MSP-1/6/7
complex can prevent PfSUB2-mediated secondary processing of MSP-1, suggesting that some antibodies targeting MSP-6 and MSP-7 may act via a different mode.
Polyclonal antibodies directed against the ectodomain of
AMA-1 effectively prevent processing and shedding of
AMA-1. Both sets of antibodies appear to function in an
entirely specific manner, having no effect on shedding of
the other protein(s). MSP-1 epitopes elicit highly inhibitory antibodies, although not as immunogenic in various
animal species when presented in the context of the
intact antigen. These findings are of relevance for the
development of vaccines based on the antigens studied
here.

Methods
Production of recombinant AMA-1 ectodomain and MSP
proteins

The P. falciparum FVO AMA-1 corresponding to
domains I-III of the ectodomain (Ile97-Lys546) was
expressed in Pichia pastoris and purified as described
previously [19,23,24]. The MSP-1 (3D7) derived proteins
were produced in Escherichia coli from synthetic codon
optimized DNA sequences as described previously [25].
The MSP-1 complex (p83/30+p38/42) as well as the
MSP-1 subunits MSP-183, MSP-130, MSP-138 and MSP142 were purified as described [26,27]. Production in E.
coli and purification of N-terminally GST-fused MSP-6
and MSP-7 precursor proteins as well as N-terminally
His6-tagged MSP-636, MSP-636Δ and MSP-722 was
described previously [11,28]. The N-terminally His6fused MSP-1 fragments MSP-142ΔEGF (Ala1327-Gln1612)
and MSP-133 (Ala1327-Leu1606) were prepared from inclusion bodies which were solubilized in buffer 1 (50 mM
Tris, pH 8.0, 4 M guanidine hydrochloride, 3 mM β-mercaptoethanol, 5 mM EDTA) and applied to Ni2+-chelate
column equilibrated with buffer 1. After washing with
buffer 2 (buffer 1 plus 10 mM imidazole), MSP-142ΔEGF or
MSP-133 was eluted with buffer 3 (buffer 1 plus 300 mM
imidazole). The eluted material was renatured by dialysis
against 50 mM Tris, pH 8.0, 1 M arginine, 5 mM DTT, 2
mM EDTA. The MSP-119 fragment (Asn1607-Asn1702) was
produced with an N-terminally fused GST-tag in soluble
form and applied to a GSH affinity chromatography in
PBS, pH 7.4, 5 mM DTT. After washing with the same
buffer p19 was eluted with PBS, pH 7.4, 5 mM DTT, 15
mM GSH. All proteins used herein were buffered in PBS,
pH 7.4.
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Antibodies
Rabbit antibodies

IgG purified from sera specific for MSP-183, MSP-130,
MSP-138, MSP-142, MSP-6 and MSP-7, were described
previously [11,22]. The preparation of IgG from preimmune serum, and of IgG against Escherichia coli protein ClpB, used as malaria unrelated control antibody,
were described previously [11,22]. For the other antibodies, groups of two or three New Zealand White rabbits
were primed on day 0 with 100 μg of purified MSP142ΔEGF, MSP-119, or MSP-636 in Freund's complete adjuvant (CFA), followed by three boosts on day 28, 42 and 56
with the same amount of protein in Freund's incomplete
adjuvant. Serum samples were withdrawn prior to each
immunization and two weeks after the last boost total
sera were collected. Purified antibody preparations (IgG)
from all rabbit sera were obtained by ammonium sulphate precipitation and stored in PBS, pH 7.4, as previously described [22].
Mouse sera

Balb/c mice were immunized with purified recombinant
AMA-1 ectodomain either in its native state or following
reduction and alkylation as described earlier [29] generating 'N' and 'R' sera.
Monoclonal antibodies

MSP-119 specific mouse mAb 12.8, 12.10, 7.5, the MSP183 specific mouse mAb 89.1, and the MSP-133 specific
human mAb X509 have all been described previously
[5,12], as has been the AMA-1 specific rat mAb 4G2 [19]
and the mouse mAb 4F3 (αRAP-1: personal communication, Dr. B. Clough, NIMR, UK).
Enzyme linked immunosorbent assay (ELISA)

Microtiter plates (96 well) were coated with recombinant
protein by overnight incubation with 0.1 ml of 100 nM
protein in 50 mM sodium carbonate buffer, pH 9.6 at 4°C.
Plates were washed twice with TBST (10 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 0.05% Tween 20) before incubation for 1 h at room temperature with blocking buffer
(TBST containing 1% milk powder). Antibodies were
diluted serially in blocking buffer and incubated with
antigen-coated plates for 2 h at room temperature. After
three washes with TBST, goat anti-rabbit IgG-alkaline
phosphatase conjugate (Sigma, Munich, Germany)
diluted 1:2,500 in blocking buffer, was added to the plates
and incubated for 1 h at room temperature. The substrate
p-nitrophenyl-phosphate (1 mg/ml in 0.96% (vol/vol)
diethanolamine, pH 9.5, and 1 mM MgCl2) was added,
and incubated for 1 h at room temperature in the dark.
The reaction was stopped with 0.1 ml of 2 M NaOH, and
absorbance was measured at 405 nm. Antibody endpoint
titers were calculated as the dilution that produced an
absorbance (optical density at 405 nm, OD405) of 1.0.
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Pre-immune antibody was used as a negative control
serum.
Culturing parasites

Plasmodium falciparum 3D7 parasites were grown under
standard conditions [30] and naturally-released free
merozoites were isolated as described [31].
Processing assays

The effect of antibodies on shedding of AMA-1 and
MSP-1 from isolated merozoites was assayed as described
[14,31]. Briefly, 3D7 merozoites purified from cultures
containing 10 mM EGTA were washed, suspended in 50
mM Tris-HCl, 5 mM CaCl2 (pH 7.6) and divided into
equal aliquots of approximately 4 × 108 merozoites, on
ice. Aliquots were supplemented with mouse sera, purified rabbit IgGs or monoclonal antibodies, PMSF or control buffers and transferred to 37°C for 2 h. In assays with
rabbit antibodies a malaria unrelated control antibody
(C) specific for the ClpB protein from Escherichia coli
was used as a control [31]. Merozoites were pelleted, and
shed AMA-148+44 or MSP-133 detected in merozoite
supernatants by western blot using mAb 4G2 or mAb
X509 respectively.
SDS-PAGE and western blotting

Parasite lysates were fractionated by SDS-PAGE under
non-reducing conditions prior to transfer to Hybond-C
extra nitrocellulose membrane (Amersham Biosciences).
Membranes were probed with mAbs as previously
described [16].
Parasite growth inhibition assay

Purified rabbit IgGs were examined for their potency in
inhibiting P. falciparum replication by measuring LDH
levels in late trophozoite/early schizont stage cultures as
described [22]. Prior to use in growth inhibition assay,
rabbit antibody preparations were preadsorbed on type A
human RBCs. For this 1 ml of antibody solution was incubated with 50 μl of RBCs (>90% haematocrit) for 1 h. The
RBCs were then pelleted by centrifugation, and supernatants were dialyzed against 100 volumes of RPMI
medium before use in assays. Plasmodium falciparum
strain 3D7 was synchronized by magnetic cell separation,
cultures were adjusted to 0.4% parasitaemia with human
type A erythrocytes at a final haematocrit of 1%, and the
final assay volume of cultures was 100 μl containing 25%
or 40% (v/v) purified rabbit antibody solution. For monitoring concentration dependencies of antibodies, antibodies were added to the assay in a total volume of 25 μl
which contained the respective amount of antibody preparation (3.125 - 25 μl) adjusted to a final volume of 25 μl
with pre-immune antibody (PI) whenever required. 25%
(v/v) purified pre-immune antibody was used as a con-

Page 4 of 12

trol. For monitoring the additive effect of antibodies,
antibodies were added to the assay in a total volume of 40
μl, which contained the respective amount of antibody
preparation (10 or 20 μl) adjusted to a final volume of 40
μl with pre-immune antibody (PI) whenever required.
40% (v/v) purified pre-immune antibody was used as a
control. Plasmodium falciparum growth was assayed
after 40 h. Inhibition was measured at 650 nm and calculated as follows: % inhibition = 100% - (ODimmune antibody ODRBC/ODpre-immune antibody - ODRBC) × 100.

Results
Inhibition of MSP-1 secondary processing by MSP-1 specific
antibodies

Secondary processing of MSP-1 is readily assayed by
monitoring the cleavage of MSP-142 into MSP-133 and
MSP-119 in preparations of isolated merozoites [31].
Monoclonal antibodies that prevent this cleavage also
inhibit invasion of RBCs by the parasite, as previously
demonstrated [32]. Since all these monoclonal antibodies
recognize epitopes within MSP-119, it is likely that they
act by steric hindrance, preventing access of PfSUB2 to
the secondary cleavage site [33]. It was, therefore, of
interest to examine whether growth inhibitory antibodies
targeting distant regions of MSP-1 also prevent secondary processing, or whether some of them act through a
different mechanism.
To allow for comparisons in this assay, concentrations
of antibodies specific for the various MSP-1 fragments
were adjusted for maximal invasion inhibition, while still
in the range of linear dependency on dilution. All αMSP1 preparations showed inhibition of secondary processing
as judged by visual analysis of the western blot data (Figure 2A), correlating well with their in vitro inhibition of
parasite multiplication. These findings were confirmed
by further experiments in which secondary processing
assays were performed using different concentrations of
αMSP-183, αMSP-142 and αMSP-142ΔEGF antibodies (Figure 2B). Throughout, levels of processing inhibition correlated with antibody concentration.
Inhibition of parasite growth in vitro by antibodies specific
for MSP-6 and MSP-7

Antibodies directed against recombinant MSP-6 and
MSP-7 inhibit parasite multiplication with comparable
efficiency to antibodies raised against MSP-1 subunits, as
previously reported [11]. To examine this observation in
more detail, rabbit antibodies raised against recombinant
MSP-6, MSP-636 and MSP-7, were analysed via ELISA
using various protein constructs as capture antigen.
Immunization with the MSP-6 precursor elicited primarily antibodies directed against the N-terminal part of the
molecule not present in the MSP-1/6/7 complex, whereas
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of whether combinations of αMSP-6 and αMSP-7 antibodies are additive in their growth inhibitory effect as
well. To address this issue, various rabbit antibodies specific for MSP-6, MSP-636 and MSP-7 were combined with
antibodies specific for the major MSP-1 subunits as well
as with each other and examined for their growth inhibitory potential. As shown in Figure 3C, all combinations
demonstrated that the antibodies targeting the various
epitopes within the MSP-1/6/7 complex act in an additive
manner.
Inhibition of MSP-1 secondary processing by antibodies
specific for MSP-6 and MSP-7

Figure 2 Inhibition of secondary processing of MSP-1 by antibodies specific for epitopes throughout the MSP-1 molecule. Secondary processing of MSP-1 in preparations of isolated merozoites was
monitored by western blot using mAb X509 to detect the appearance
of MSP-133 in merozoite supernatants. (A) Shown is processing of MSP142 after incubation with medium alone (control), the serine protease
inhibitor PMSF (a very effective inhibitor of PfSUB2), pre-immune antibody (PI), malaria unrelated control antibody (C), or with rabbit antibodies specific for various MSP-1 fragments. (B) Shown is the
dependency of MSP-1 secondary processing on antibody concentration. Merozoites were incubated in the presence of pre-immune antibody (PI), malaria unrelated control antibody (C), PMSF, or varying
amounts of αMSP-183, αMSP-142 or αMSP-142ΔEGF antibodies ranging in
concentration from 1% to 10% (v/v) antibody solution. The two sets of
panels show western blot results of two different loadings of supernatant samples on SDS-PAGE. The additional bands that appear on all the
blots with increasing concentrations of test IgG are due to low-level
non-specific recognition of IgG heavy and light chains on the blots by
the secondary antibodies used. Loading controls (using mAb 4G2 to
detect shedding of the AMA-1 ectodomain) confirmed equal loading
in all lanes (data not shown).

good titers against the processed product were obtained
upon immunization with MSP-636 (Figure 3A). Surprisingly, αMSP-636 antibodies reacted better with the MSP-6
precursor than with the inducing antigen MSP-636. Moreover, when the αMSP-6 and αMSP-636 antibodies were
probed against MSP-636 and MSP-636Δ, no difference
between the two capture antigens was observed, indicating that the missing C-terminal 51 aa of MSP-636Δ are
virtually non-immunogenic in this context.
Immunization with the MSP-7 precursor induced antibodies directed primarily against the N-terminally
located processing product, which is not part of the MSP1/6/7 complex, whereas the C-terminal MSP-722 (Figure
1), when used as capture antigen, revealed only low titers
showing its low immunogenicity in the context of the
MSP-7 precursor molecule (Figure 3B).
As previously reported [22], combinations of antibodies
directed against different parts of MSP-1 have an additive
effect on growth inhibition in vitro, raising the question

It was of interest to examine whether invasion-inhibitory
antibodies targeting MSP-636 and MSP-722 could inhibit
secondary processing of MSP-1. As shown in Figure 4,
antibodies targeting MSP-6 and its processed form MSP636, as well as antibodies specific for MSP-7, all reproducibly inhibited MSP-1 secondary processing, confirming
that this maturation step is highly sensitive to antibody
binding even when the antibodies specifically target the
MSP-6 and MSP-7-derived components of the complex.
Processing-inhibitory antibodies act in a target-specific
manner

Shedding (secondary cleavage) of both MSP-1 and AMA1 from the merozoites surface is mediated by the same
protease, PfSUB2 [14,16]. Previous work by others has
shown that antibodies against AMA-1 effectively interfere with AMA-1 shedding, and it has been suggested
that this may represent one mechanism by which
αAMA1 antibodies prevent invasion [17,20]. In view of
the above findings, it was explored whether antibodies
targeting either the MSP-1/6/7 complex or AMA-1 could
affect the processing and shedding of the alternate surface protein. Using mouse sera raised against recombinant AMA-1 ectodomain [19,23], indeed antibodies
specific for correctly folded AMA-1 - but not those raised
against reduced and alkylated AMA-1 - were found to
effectively inhibited processing and shedding of this protein (Figure 5A). However, neither set of sera had any discernible effect on secondary processing of MSP-1 in the
same merozoite preparations (Figure 5A, lower panel).
Interestingly, no inhibition of AMA-1 processing was
observed in the presence of the AMA-1-specific monoclonal antibody 4G2, which contrasts with the findings of
Dutta et al [17]. Further exploration showed that the
effect of αAMA-1 sera was dose-dependent and required
their presence during the assay (Figure 5B). Next the
most effective αAMA-1 serum (N5) was compared with
monoclonal antibodies known to inhibit MSP-1 processing (mAb 12.8, mAb 12.10, mAb 89.1) (Figure 6C). The
results confirmed that processing inhibition by these
antibodies was exquisitely antigen-specific: N5 serum sig-
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Figure 3 Inhibition of parasite growth by combinations of antibodies directed towards MSP-1, MSP-6 and MSP-7. (A) Immunogenicity of recombinant MSP-6 and MSP-636 in rabbits. Endpoint titers were determined against GST (only for αMSP-6, since it was generated using recombinant
MSP-6 carrying a GST-tag), MSP-6, MSP-636, and MSP-636Δ. (B) Immunogenicity of recombinant MSP-7 in rabbits. Endpoint titers were determined
against GST, MSP-7, and MSP-722. (C) Growth of P. falciparum strain 3D7 in the presence of rabbit antibodies specific for MSP-183, MSP-130, MSP-138, and
MSP-142 as well as rabbit antibodies specific for MSP-6, MSP-636 and MSP-7. All antibody preparations were diluted to produce between 10-50% inhibition of parasite growth. The indicated combinations were assayed for growth inhibition of P. falciparum strain 3D7 via activity of parasite-derived
LDH [22]. Antibodies were added to the assay mixtures in a volume of 40 μl (40% of final assay volume) containing 10 μl or 20 μl (10 or 20% of final
assay volume) of antibody preparations, as indicated, and whenever necessary adjusted to 40 μl with rabbit pre-immune antibody. Pre-immune antibody (40% v/v) was used as a control. Growth inhibition is presented as percent of control. Dark columns, inhibition calculated from the measured
contribution of the individual antibody preparations; light columns, inhibition measured. Error bars show standard deviations derived from triplicate
assays. Representative results of one of two experiments are shown.

nificantly blocked AMA-1 shedding but had no effect on
MSP-1 processing, and, vice versa, the αMSP-1 monoclonal antibodies strongly inhibited MSP-1 processing without affecting AMA-1. Again, these effects were dosedependent, and in the presence of both N5 serum and
mAb 12.8, processing of both MSP-1 and AMA-1 was
effectively blocked (Figure 5D).

Inhibition of parasite growth in vitro by MSP-142 specific
antibodies

Previous studies [22], examining the growth-inhibitory
potential of rabbit antibodies raised against recombinant
proteins corresponding to the four primary processing
products of MSP-1, revealed not only that antibodies targeting epitopes throughout MSP-1 can effectively inter-

Woehlbier et al. Malaria Journal 2010, 9:77
http://www.malariajournal.com/content/9/1/77

Figure 4 Inhibition of secondary processing of MSP-1 by antibodies specific for MSP-6 and MSP-7. Processing of MSP-142 after incubation for 2 h with PMSF, medium alone (2 h control), or medium
supplemented with 5 or 10% (v/v) rabbit antibody specific for MSP-6,
MSP-636 or MSP-7. Loading controls (using mAb 4G2 to detect shedding of the AMA-1 ectodomain) confirmed equal loading in all lanes
(data not shown).

fere with parasite multiplication in vitro, but also that the
four processing products of MSP-1 differ significantly in
their immunogenicity, as reflected by antibody titers in
the serum of immunized animals and of individuals living
in malaria endemic regions of West Africa [22] and India
[28]. The most immunogenic processing product was
found to be MSP-142, which also encompasses the secondary processing product MSP-119 (Figure 1A). Immunogenicity did not correlate with the inhibitory potential
of the respective antibody preparations [22].
To further dissect the antibody response against MSP142, the rabbit αMSP-142 antibodies were analysed by
ELISA against recombinant full-length MSP-1 [25], MSP142, MSP-133, and a truncated form of MSP-142, called
MSP-142ΔEGF. This latter protein contains the entire
cleavage site at the junction between MSP-133 and MSP119 and an adjacent six amino acids comprising a C-terminal extension into the N-terminus of MSP-119, but it lacks
the C-terminal EGF-like domains. The results of these
assays (Figure 6A) indicated that by far the most immunogenic region of MSP-142 lies within the MSP-119 portion of the molecule, since about 70% of the αMSP-142
antibodies were found to be directed against this latter
region. As expected, the αMSP-142ΔEGF antibodies
showed little reactivity with MSP-119, (the low reactivity
observed is possibly due to the six amino acid residues
shared by the two proteins). However, the αMSP-142ΔEGF
antibodies exhibited a high titer against MSP-133 compared to that obtained by immunization with full-length
MSP-142. A major fraction of these antibodies presumably targets epitopes, which do not efficiently compete in
the context of full-length MSP-1 or MSP-142 (Figure 6A).
By contrast MSP-119 alone (fused C-terminally to GST)
was significantly less immunogenic, indicating a strong
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context dependency, which apparently is favourable only
when this sequence is embedded in intact MSP-142.
It is well documented that antibodies directed against
MSP-119 can efficiently inhibit parasite growth in vitro,
and that humoral responses against MSP-119-based
experimental vaccines can be protective in animal models
[34-36]. It was, therefore, of interest to examine whether
antibodies raised against MSP-142ΔEGF could inhibit parasite growth in vitro. As shown in Figure 6B αMSP-142ΔEGF
antibodies indeed inhibited parasite multiplication by
50% when 25% v/v purified antibodies are used in the
assay. In comparison αMSP-142 and αMSP-119 reach the
same level of inhibition with about 15% and 10% v/v purified antibodies in used in the assay. Relating titers of the
antibody preparations shown in Figure 6A with inhibitory
potential, the most effective antibodies appear to target
MSP-119.
In summary, these analyses support previous findings
that multiple epitopes throughout MSP-1 can elicit antibodies, which inhibit parasite growth in vitro.

Discussion
Several lines of evidence indicate that humoral immune
responses against P. falciparum merozoite surface antigens are major, if not decisive, contributors to the partial
immunity acquired by individuals subject to repeated
infections. Accordingly, numerous efforts aiming at
developing vaccines against P. falciparum malaria have
focused on such antigens, of which MSP-1 and AMA-1
are particularly promising candidates.
As recently shown [11,22], parasite growth in vitro is
efficiently inhibited by antibodies targeting different
areas of the multipartite MSP-1/6/7 complex, indicating a
multitude of epitopes potentially relevant for vaccine
development. Such polyclonal antibodies preparations,
while primarily preventing invasion of erythrocytes by
merozoites, are also capable of inhibiting the intracellular
development of the parasite [37]. Moreover, as also
revealed in these studies, MSP-1 exhibits an immunogenicity profile in which some epitopes, which induce
highly effective inhibitory antibodies, are rather poorly
recognized by the immune system as reflected by low
titers in serum of mice, rabbits, monkeys and humans.
For vaccine development it is important to not only
learn more about relevant epitopes of candidate antigens
but also to gain insights into mechanisms by which
growth inhibitory antibodies act. Prevention of PfSUB2
mediated secondary processing of MSP-1 and AMA-1, a
prerequisite for the shedding of these antigens from the
surface of the parasite, has been identified as a plausible
mechanism by which inhibitory antibodies targeting
these proteins function [17,18,20,38].
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Figure 5 Specificity of processing inhibition by antibodies targeting MSP-1/MSP-6/MSP-7 or AMA-1. Processing of AMA-1 and of MSP-1 was
detected by western blot using mAb 4G2 and mAb X509 respectively (to identify the processing products AMA-144/48 and MSP-133 respectively). 'Start'
indicates samples taken at the beginning of the assay, before incubation of merozoites. (A) Incubation of isolated merozoites in the absence of serum
(control), or in the presence of normal mouse sera, (NMS1 and NMS2), or with polyclonal mouse sera raised against reduced and alkylated (R2-R5) or
correctly folded (N2-N5) PfAMA-1 ectodomain. Additionally, purified mAb 4G2 was tested for processing inhibition. (B) Dependency of processing on
antibody concentration. Merozoites were either incubated in the absence of the sera (tracks 2, 3 and 4 from the left) or in the presence of varying
amounts of N3 or N5 serum - presented in terms of percentage (v/v) of serum. The two sets of panels show western blot results of two different loadings of supernatant samples on SDS-PAGE. (C) Processing in presence of AMA-1 antiserum N5, as well as monoclonal antibodies mAb 12.8, mAb 12.10,
mAb 7.5 specific for MSP-119, mAb 89.1 specific for MSP-183 and control mAb 4F3. (D) Inhibition of AMA-1 processing by varying amounts of αAMA-1
serum N5, and inhibition of MSP-142 processing by varying amounts of mAb 12.8. Inhibition of processing of both AMA-1 and MSP-1 in the presence
of antibodies against both proteins (track 11).

Here it was examined whether antibodies specific for
the four subunits of MSP-1, MSP-6, or MSP-7 - all of
which efficiently inhibit parasite growth in vitro - also
affect secondary processing and shedding of the complex,
or whether additional mechanisms of action may have to
be envisioned. The data presented clearly show that antibodies targeting each of the distinct components of the

MSP-1/6/7 complex can indeed perturb the function of
PfSUB2, and thus are capable of interrupting this important step in the parasite's maturation pathway.
These results are interesting in several regards. Firstly,
it would not necessarily be predicted that secondary
cleavage, which occurs close to the C-terminus of MSP-1
would be affected by antibodies binding to sites likely to
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Figure 6 Inhibition of parasite growth by rabbit αMSP-1 antibodies. (A) Immunogenicity of MSP-142, MSP-142ΔEGF and MSP-119 in rabbits. Endpoint titers were determined by ELISA against the whole of MSP-1 (in the form of the p83/30+p38/42 heterodimer), MSP-142, MSP-142ΔEGF, MSP-133, or
MSP-119 as shown. For the αMSP-119 antibodies the reciprocal titer directed against GST was 22910 +/- 890 (not shown). Error bars show standard deviations. (B) Growth of P. falciparum strain 3D7 was monitored in the presence of the indicated antibodies at concentrations ranging from 3.125 to
25% (v/v). Pre-immune antibody (25% v/v) was used as a control. Growth inhibition is presented as percent of control. Error bars show standard deviations.

be rather distant from the cleavage site, e.g. within MSP183, or even within MSP-6 and MSP-7. This may indicate
that antibodies bound to the complex may simply sterically hinder access of PfSUB2 to its substrate near the
MSP-1 C-terminus. Alternatively, the MSP-1/6/7 complex may constitute a rather dynamic structure sensitive
to conformational perturbations, which may occur in any
of its domains when antibodies bind. Detailed structurefunction studies of the MSP-1/6/7 complex are necessary
to provide more insight into either of these hypotheses.
Second, as the proteolytic action of PfSUB2 is thought to
be a prerequisite for the generation of invasion competent merozoites, it is of interest to note that the MSP-1/6/
7 complex obviously offers many targets for antibodies
through which the action of PfSUB2 can be inhibited.
Indeed, combinations of antibodies targeting different
subunits of the complex act in an additive manner. In the
context of vaccine development it could, therefore, be of
considerable advantage to combine these antigens. Third,
it could be shown that inhibitory polyclonal antibodies
raised against subunits of the MSP-1/6/7 complex and
against the AMA-1 ectodomain respectively, act in a fully
specific and independent manner. They interfere neither
positively nor negatively with the processing of the
"other" protein, suggesting that at least at this stage there
is no direct cooperation between these surface proteins.
The observation that the invasion-inhibitory αAMA-1
monoclonal antibody 4G2 does not affect processing of
AMA-1 is in contrast with the earlier findings of Dutta et
al [17]. There is no explanation for this discrepancy, but
in fact the findings are perfectly in accord with previous
data indicating that 4G2 blocks invasion by interfering
with interactions between AMA-1 and a partner parasite
protein called RON4, implicated in formation of the mov-

ing junction between the parasite and host erythrocyte at
invasion [39].
When looking at some results described previously [22]
and the data reported here in a more quantitative way,
two observations deserve discussion in more detail: (i) it
appears that some of the most effective MSP-1-specific
inhibitory antibodies are elicited by epitopes which are
not efficiently presented to the immune system, under
natural as well as under laboratory (immunization of laboratory animals with purified antigen) conditions; (ii)
antibodies directed against MSP-6 and particularly
against MSP-7 are more effective in inhibiting parasite
growth than in preventing secondary processing of MSP1.
To address the first issue, the humoral response against
the most immunogenic region of MSP-1 covered by
MSP-142 was analysed further. The striking results of
these experiments show that epitopes within the highly
immunogenic subregion of MSP-142, i.e. within MSP-119,
apparently outcompete potentially valuable epitopes
located upstream within MSP-133/MSP-142ΔEGF. Thus,
immunization of rabbits with antigen devoid of the two
highly immunogenic C-terminal EGF-like domains elicits
high titers of growth inhibitory antibodies, which target
regions upstream of MSP-119. These data demonstrate
that epitopes within the MSP-1 complex, though not efficiently recognized by the immune system when presented in their natural context, are nevertheless
accessible at the surface of the parasite, where the binding
of their respective antibodies effectively prevents secondary processing of MSP-1 and thus RBC invasion. Similar
constraints likely hold for epitopes located within MSP130 and MSP-138 [22].
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The recognition of the majority of MHC II restricted
epitopes depends strongly on structural parameters
defined largely by the context in which they are embedded in the antigen [40], whereby local flexibility may play
an additional role [41]. Results described here and previously [11,22] have revealed that some of the MSP-1
encoded epitopes which elicit the most effective inhibitory antibodies, are not efficiently recognized by the
immune system when presented in the context of the
complete antigen, although they are apparently readily
accessible to antibodies at the surface of the parasite. The
low immunogenicity of such epitopes may actually be one
of the reasons why long-lasting, pathogen-clearing
humoral responses develop only after repeated exposure
to the parasite. For vaccine development it appears therefore important to reconcile particularly such epitopes.
As previously shown [22], polyclonal antibodies specific for the four subunits of MSP-1 inhibit parasite
growth not only individually but also when combined,
acting in an additive mode. Here, the same holds true
when antibodies against MSP-6 and MSP-7 are included
in the analysis. In addition antibodies raised against the
MSP-6 precursor are more effective inhibitors of secondary MSP-1 processing and of parasite growth, than those
induced by MSP-636 (the processed and MSP-1 associated
form). These findings suggest that either the MSP-6 precursor more efficiently induces antibodies that bind to
MSP-636, or that antibodies directed towards the N-terminal portion of the MSP-6 precursor (not present in the
mature MSP-1/6/7 complex) act independently and
through a different mechanism. Equally interesting is the
observation that antibodies specific for the MSP-7 precursor, which effectively inhibit parasite growth [11],
have only a minor effect on the secondary processing of
MSP-1, again suggesting further mechanisms of action.

Conclusions
The present study has yielded a number of insights,
which may be summarized as follows: (i) secondary processing of MSP-1, a prerequisite for antigen shedding and
subsequent RBC invasion can be inhibited by antibodies
targeting numerous epitopes distributed throughout the
MSP-1/6/7 complex; (ii) when combined, these antibodies act in an additive manner; (iii) antibodies which prevent PfSUB2 mediated processing of AMA-1 and MSP-1
respectively act independently and do not affect the processing of the alternate protein; (iv) data obtained with
MSP-6 and MSP-7 suggest additional mechanisms by
which antibodies against the surface proteins studied
here may inhibit parasite growth; (v) by dissecting the
immunogenicity of MSP-142 further, epitopes were
revealed which, in the context of the antigen, do not
induce an effective antibody response, even though at the
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parasite surface they are accessible to their respective
antibodies and capable of mediating efficient inhibition
of secondary processing and erythrocyte invasion.
The findings presented here provide new insights in the
mode of action of antibodies targeting the merozoite surface antigens MSP-1, MSP-6, MSP-7 and AMA-1, and
suggest that for optimal vaccine development a more
detailed understanding of the structure-function relationship of these antigens is necessary. Equally, these
findings provide further support for the feasibility of the
development of vaccines or immunization regimens
based on these antigens.
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